Malignancies Clinical Trials in Dallas, Texas
14 recruitingDallas, Texas
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 1Phase 2
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Lymphoid Malignancies
AVM Biotechnology Inc144 enrolled11 locationsNCT04329728
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+2 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 2
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled3 locationsNCT07271667
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Solid Tumor Malignancies
Kumquat Biosciences Inc.84 enrolled15 locationsNCT06994806
Recruiting
Phase 1Phase 2
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Colorectal CarcinomaBladder CancerSolid Tumor Malignancies+2 more
Tasca Therapeutics150 enrolled13 locationsNCT07030257
Recruiting
Phase 1Phase 2
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Advanced or Metastatic Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.140 enrolled18 locationsNCT05023486
Recruiting
Phase 1Phase 2
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Solid Malignancies
Carrick Therapeutics Limited50 enrolled6 locationsNCT06600789
Recruiting
Phase 1
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc60 enrolled9 locationsNCT05780034
Recruiting
Phase 1
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Brain Metastases From Solid TumorsSolid Tumor Malignancies
A2A Pharmaceuticals Inc.86 enrolled5 locationsNCT06136884
Recruiting
Phase 1Phase 2
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Advanced Solid Malignancies
Georgiamune Inc111 enrolled11 locationsNCT06028074
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839